Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3714 USD | +23.02% | +48.62% | -4.77% |
Business Summary
Number of employees: 102
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Artificial Intelligence-enabled in Vitro Diagnostics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Michael Donovan
CTO | Chief Tech/Sci/R&D Officer | 70 | 18-03-14 |
Joseph Hutson
PRN | Corporate Officer/Principal | - | 21-07-21 |
Sales & Marketing | - | 21-06-06 | |
Salim Hamir
SEC | Corporate Secretary | - | 18-05-31 |
Jed Fulk
SAM | Sales & Marketing | 64 | 21-10-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Erik Lium
BRD | Director/Board Member | 56 | 18-09-30 |
Catherine Coste
BRD | Director/Board Member | 58 | 23-06-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,368,191 | 94,996,551 ( 61.54 %) | 0 | 61.54 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.95% | 15.51B | |
-57.29% | 2.01B | |
+13.19% | 1.79B | |
-15.17% | 1.36B | |
+26.85% | 1.28B | |
+9.65% | 823M | |
-33.05% | 738M | |
-36.55% | 692M | |
+27.59% | 605M |
- Stock Market
- Equities
- RENX Stock
- RNLX Stock
- Company Renalytix Plc